Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice

Annals of the New York Academy of Sciences

Volumn 977, Issue , 2002, Pages 45-64

  Aliev, Gjumrakch ^a,b,e   Seyidova, Dilara ^a   Neal, Maxwell L ^a   Shi, Jiong ^b   Lamb, Bruce T ^b   Siedlak, Sandra L ^b   Vinters, Harry V ^c   Head, Elizabeth ^d   Perry, George ^b   Lamanna, Joseph C ^a,b   Friedland, Robert P ^b   Cotman, Carl W ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Free radicals; Metabolism; Mitochondria; Neurodegeneration; Oxidative stress; Vascular factors

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AMYLOID BETA PROTEIN; CYTOCHROME C OXIDASE; MITOCHONDRIAL DNA;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; BRAIN ATHEROSCLEROSIS; CELL COMPARTMENTALIZATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; GENE DELETION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS;

EID: 0036449696     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04798.x     Document Type: Conference Paper

References (98)

1. Aliev, G., M.A. Smith, D. Seyidova et al. 2002. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol. 12: 21-35.
2. De la Torre, J.C. 2002. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke 33: 1152-1162.
3. De la Torre, J.C. 2000. Critically attained threshold of cerebral hypoperfusion: The CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol. Aging 21: 331-342.
4. Kalaria, R.N. 1999. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann. N.Y. Acad. Sci. 893: 113-125.
5. Kalaria, R.N. 2000. The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging 21: 321-330.
6. Kalaria, R.N. & C. Ballard. 1999. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 13: S115-S123.
7. Baggio, G., S. Donazzan, D. Monti et al. 1998. Lipoprotein(a) and lipoprotein profile in healthy centenarians: A reappraisal of vascular risk factors. FASEB J. 12: 433-437.
8. Knebl, J., P. Defazio, M.B. Clearfield et al. 1994. Plasma lipids and cholesterol esterification in Alzheimer's disease. Mech. Ageing Dev. 73: 69-77.
9. Koudinov, A.R., T.T. Berezov & N.V. Koudinova. 1998. Alzheimer's amyloid beta and lipid metabolism: A missing link? FASEB J. 12: 1097-1099.
10. Coyle, J.T. & P. Puttfarcken. 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695.
11. Smith, M.A., G. Perry, P.L. Richey et al. 1996. Oxidative damage in Alzheimer's [letter]. Nature 382: 120-121.
12. Smith, M.A., P.L. Richey, L.M. Sayre et al. 1997. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17: 2653-2657.
13. Smith, M.A., L.M. Sayre & G. Perry. 1996. Is Alzheimer's disease of oxidative stress? Alzheimer's Dis. Rev. 1: 63-67.
14. Smith, M.A., G.J. Petot & G. Perry. 1997. Diet and oxidative stress: A novel synthesis of epidemiological data on Alzheimer's disease. Alzheimer's Dis. Rev. 2: 58-60.
15. Perry, G., A. Nunomura, K. Hirai et al. 2000. Oxidative damage in Alzheimer's disease: The metabolic dimension. Int. J. Dev. Neurosci. 18: 417-421.
16. Smith, M.A., C.A. Rottkamp, A. Nunomura et al. 2000. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502: 139-144.
17. Lovell, M.A., C. Xie & W.R. Markesbery. 1998. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51: 562-566.
18. Prasad, M.R., M.A. Lovell, M. Yatin et al. 1998. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res. 23: 81-88.
19. Markesbery, W.R. 1997. Oxidative stress hypothesis in Alzheimer's disease. Free Radical Biol. Med. 23: 134-147.
20. Markesbery, W.R. & J.M. Carney. 1999. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9: 133-146.
21. Mecocci, P., U. MacGarvey, A.E. Kaufman et al. 1993. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 34: 609-616.
22. Mecocci, P., U. MacGarvey & M.F. Beal. 1994. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36: 747-751.
23. Mecocci, P., M.F. Beal, R. Cecchetti et al. 1997. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol. Chem. Neuropathol. 31: 53-64.
24. Nunomura, A., G. Perry, G. Aliev et al. 2001. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60: 759-767.
25. Nunomura, A., G. Perry, K. Hirai et al. 1999. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann. N.Y. Acad. Sci. 893: 362-364.
26. Nunomura, A., G. Perry, M.A. Pappolla et al. 1999. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19: 1959-1964.
27. Castellani, R.J., K. Hirai, G. Aliev et al. 2002. The role of mitochondrial dysfunction in Alzheimer disease. J. Neurosci. Res. In press.
28. Sayre, L.M., D.A. Zelasko, P.L. Harris et al. 1997. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68: 2092-2097.
29. Smith, M.A., S. Taneda, P.L. Richey et al. 1994. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. U.S.A. 91: 5710-5714.
30. Cirillo, R., G. Aliev, E.J. Hornby et al. 1994. Endothelium as a therapeutical target in peripheral occlusive arterial diseases: Consideration for pharmacological interventions. Pharmacol. Res. 29: 293-311.
31. Granger, D.N., J.N. Benoit, M. Suzuki & M.B. Grisham. 1989. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am. J. Physiol. 257: G683-G688.
32. Sala, A., G.M. Aliev, G. Rossoni et al. 1996. Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit. Blood 87: 1824-1832.
33. Salvatico, E., G.M. Aliev, D. Novello & M. Prosdocimi. 1994. Functional depression of isolated perfused rat heart mediated by activated leukocytes: Protective effect of cloricromene. J. Cardiovasc. Pharmacol. 24: 638-647.
34. Cirillo, R., E. Salvatico, G. Aliev & M. Prosdocimi. 1992. Effect of cloricromene during ischemia and reperfusion of rabbit hindlimb: Evidence for an involvement of leukocytes in reperfusion-mediated tissue and vascular injury. J. Cardiovasc. Pharmacol. 20: 969-975.
35. Aliev, G., P. Bodin & G. Burnstock. 1998. Free radical generators cause changes in endothelial and inducible nitric oxide synthases and endothelin-1 immunoreactivity in endothelial cells from hyperlipidemic rabbits. Mol. Genet. Metab. 63: 191-197.
36. Aliev, G., J. Shi, J.C. Lamanna et al. 2000. Atherosclerotic-like changes of the wall of cerebral microvessels in transgenic mice overexpressing amyloid β. Neurobiol. Aging 21: 1224.
37. Aliev, G., J. Shi, G. Perry et al. 2000. Decreased constitutive nitric oxide synthase, but increased inducible nitric oxide synthase and endothelin-1 immunoreactivity in aortic endothelial cells of Donryu rats on a cholesterol-enriched diet. Anat. Rec. 260: 16-25.
38. Aliev, G., M.A. Smith, M. Turmaine et al. 2001. Atherosclerotic lesions are associated with increased immunoreactivity for inducible nitric oxide synthase and endothelin-1 in thoracic aortic intimal cells of hyperlipidemic Watanabe rabbits. Exp. Mol. Pathol. 71: 40-54.
39. Aliev, G., M.A. Smith, D. Seyidova et al. 2002. Increased expression of NOS and ET-1 immunoreactivity in human colorectal metastatic liver tumours is associated with selective depression of constitutive NOS immunoreactivity in vessel endothelium. J. Submicrosc. Cytol. Pathol. 34: 37-50.
40. Shankar, A., M. Loizidou, G. Aliev et al. 1998. Raised endothelin 1 levels in patients with colorectal liver metastases. Br. J. Surg. 85: 502-506.
41. De la Torre, J.C. & G.B. Stefano. 2000. Evidence that Alzheimer's disease is a microvascular disorder: The role of constitutive nitric oxide. Brain Res. Rev. 34: 119-136.
42. Schulz, J.B, R.T. Matthews, T. Klockgether et al. 1997. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 174: 193-197.
43. Beckman, K.B. & B.N. Ames. 1998. The free radical theory of aging matures. Physiol. Rev. 78: 547-581.
44. Beckman, K.B. & B.N. Ames. 1998. Mitochondrial aging: Open questions. Ann. N.Y. Acad. Sci. 854: 118-127.
45. Beckman, K.B. & B.N. Ames. 1999. Endogenous oxidative damage of mtDNA. Mutat. Res. 424: 51-58.
46. Wallace, D.C. 1997. Mitochondrial DNA in aging and disease. Sci. Am. 277: 40-47.
47. Wallace, D.C., C. Stugard, D. Murdock et al. 1997. Ancient mtDNA sequences in the human nuclear genome: A potential source of errors in identifying pathogenic mutations. Proc. Natl. Acad. Sci. U.S.A. 94: 14900-14905.
48. Wallace, D.C. 1999. Mitochondrial diseases in man and mouse. Science 283: 1482-1488.
49. Aliev, G., G. Perry, D. Seyidova et al. 2002. The role of mitochondria failure in the development of AD-like pathology in an aged transgenic mouse model of AD. Neurobiol. Aging 23(S1): 1525.
50. Aliev, G., M.A. Smith, H. Vinters et al. 1999. Mitochondria abnormalities mark vulnerable neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 58: 511.
51. Aliev, G., J. Shi, G. Perry et al. 2000. Neuronal mitochondrial abnormalities in yeast artificial chromosome (YAC) transgenic mice overexpressing amyloid precursor protein (APP). In Annual Meeting of the Society for Neuroscience, New Orleans. Abstract 301.4.
52. Aliev, G., G. Perry, B.T. Lamb et al. 2001. Aged YAC AβPP transgenic mice develop atherosclerotic lesions and mitochondria DNA deletions in brain microvessels without exogenous cholesterol supplementation. In Annual Meeting of the Society for Neuroscience, San Diego. Abstract 752.12.
53. Beal, M.F. 1995. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38: 357-366.
54. Bonilla, E., K. Tanji, M. Hirano et al. 1999. Mitochondrial involvement in Alzheimer's disease. Biochim. Biophys. Acta 1410: 171-182.
55. Fiskum, G., A.N. Murphy & M.F. Beal. 1999. Mitochondria in neurodegeneration: Acute ischemia and chronic neurodegenerative diseases. J. Cereb. Blood Flow Metab. 19: 351-369.
56. Hirai, K., G. Aliev, A. Nunomura et al. 2001. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21: 3017-3023.
57. De la Torre, J.C. 1997. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann. N.Y. Acad. Sci. 826: 75-91.
58. Stewart, P.A., K. Hayakawa, M.A. Akers & H.V. Vinters. 1992. A morphometric study of the blood-brain barrier in Alzheimer's disease. Lab. Invest. 67: 734-742.
59. Joachim, C.L., J.H. Morris & D.J. Selkoe. 1989. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am. J. Pathol. 135: 309-319.
60. Coria, F., E. Castano, F. Prelli et al. 1988. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab. Invest. 58: 454-458.
61. Kawai, M., R.N. Kalaria, S.I. Harik & G. Perry. 1990. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am. J. Pathol. 137: 1435-1446.
62. Tagliavini, F., J. Ghiso, W.F. Timmers et al. 1990. Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab. Invest. 62: 761-767.
63. Etiene, D., J. Kraft, N. Ganju et al. 1998. Cerebrovascular pathology contributes to the heterogeneity of Alzheimer's disease. J. Alzheimer's Dis. 1: 119-134.
64. De Jong, G.I., R.A. De Vos, E.N. Steur & P.G. Luiten. 1997. Cerebrovascular hypoperfusion: A risk factor for Alzheimer's disease? Animal model and postmortem human studies. Ann. N.Y. Acad. Sci. 826: 56-74.
65. Friston, K.J. & R.S. Frackowiak. 1991. Cerebral function in aging and Alzheimer's disease: The role of PET. Electroencephalogr. Clin. Neurophysiol. 42: 355-365.
66. Kumar, A., M.B. Schapiro, J.V. Haxby et al. 1990. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. J. Psychiatr. Res. 24: 97-109.
67. Meguro, K., X. Blaizot, Y. Kondoh et al. 1999. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET: Implications for Alzheimer's disease. Brain 122: 1519-1531.
68. Kuo, Y.M., M.R. Emmerling, C.L. Bisgaier et al. 1998. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem. Biophys. Res. Commun. 252: 711-715.
69. Montine, T.J., K.S. Montine & L.L. Swift. 1997. Central nervous system lipoproteins in Alzheimer's disease. Am. J. Pathol. 151: 1571-1575.
70. Grant, D.N. 1997. Dietary links to Alzheimer's disease. Alzheimer's Dis. Rev. 2: 42-55.
71. Refolo, L.M., M.A. Pappolla, B. Malester et al. 2000. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7: 321-331.
72. Sparks, D.L. 1997. Coronary artery disease, hypertension, ApoE, and cholesterol: A link to Alzheimer's disease? Ann. N.Y. Acad. Sci. 826: 128-146.
73. Sparks, D.L., Y.M. Kuo, A. Roher et al. 2000. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation: Preliminary observations. Ann. N.Y. Acad. Sci. 903: 335-344.
74. Duff, K. 1998. Transgenic models for Alzheimer's disease. Neuropathol. Appl. Neurobiol. 24: 101-103.
75. Lamb, B.T., L.M. Call, H.H. Slunt et al. 1997. Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. Hum. Mol. Genet. 6: 1535-1541.
76. Lamb, B.T., K.A. Bardel, L.S. Kulnane et al. 1999. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat. Neurosci. 2: 695-697.
77. Neve, R.L. & N.K. Robakis. 1998. Alzheimer's disease: A re-examination of the amyloid hypothesis. Trends Neurosci. 21: 15-19.
78. Wong, P.C., H. Cai, D.R. Borchelt & D.L. Price. 2002. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 5: 633-639.
79. Shi, J., G. Perry, M.S. Berridge et al. 2002. Labeling of cerebral amyloid β deposits in vivo using nasally administrated basic fibroblast growth factor and serum amyloid P component. J. Nucl. Med. 43: 1044-1051.
80. Shi, J., G. Perry, G. Aliev et al. 1999. Serum amyloid P is not present in amyloid beta deposits of a transgenic animal model. Neuroreport 10: 3229-3232.
81. Chen, G., K.S. Chen, J. Knox et al. 2000. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408: 975-979.
82. Lin, B., M.D. Ginsberg & R. Busto. 2001. Hyperglycemic, but not normoglycemic global ischemia induces marked early intraneuronal expression of beta-amyloid precursor protein. Brain Res. 888: 107-116.
83. Khachaturian, Z.S. 1985. Progress of research on Alzheimer's disease: Research opportunities for behavioral scientists. Am. Psychol. 40: 1251-1255.
84. Khachaturian, Z.S. 1985. Diagnosis of Alzheimer's disease. Arch. Neurol. 42: 1097-1105.
85. Mirra, S.S., A. Heyman, D. McKeel et al. 1991. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
86. Aliev, G., A. Mironov, R. Cirillo et al. 1993. Evidence for the presence of early vascular lesions in newborn Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis 101: 17-24.
87. Aliev, G., R. Cirillo, E. Salvatico et al. 1993. Changes in vessel ultrastructure during ischemia and reperfusion of rabbit hindlimb: Implications for therapeutic intervention. Microvasc. Res. 46: 65-76.
88. Aliev, G., S. Miah, M. Turmaine & G. Burnstock. 1995. An ultrastructural and immunocytochemical study of thoracic aortic endothelium in aged Sprague-Dawley rats. J. Submicrosc. Cytol. Pathol. 27: 477-490.
89. Wallace, D.C., G. Singh, M.T. Lott et al. 1988. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 242: 1427-1430.
90. Blass, J.P. 2001. Brain metabolism and brain disease: Is metabolic deficiency the proximate cause of Alzheimer dementia? J. Neurosci. Res. 66: 851-856.
91. Blass, J.P. 2000. The mitochondrial spiral: An adequate cause of dementia in the Alzheimer's syndrome. Ann. N.Y. Acad. Sci. 924: 170-183.
92. Blesa, R., E. Mohr, R.S. Miletich et al. 1996. Cerebral metabolic changes in Alzheimer's disease: Neurobehavioral patterns. Dementia 7: 239-245.
93. Minoshima, S., B. Giordani, S. Berent et al. 1997. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42: 85-94.
94. Wong-Riley, M., P. Antuono, K.C. Ho et al. 1997. Cytochrome oxidase in Alzheimer's disease: Biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Res. 37: 3593-3608.
95. Parker, W.D.J., S.J. Boyson & J.K. Parks. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26: 719-723.
96. Davis, R.E., S. Miller, C. Herrnstadt et al. 1997. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 94: 4526-4531.
97. Kish, S.J., C. Bergeron, A. Rajput et al. 1992. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 59: 776-779.
98. Mutisya, E.M., A.C. Bowling & M.F. Beal. 1994. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63: 2179-2184.